Literature DB >> 28041629

Prevalence of and outcomes from Staphylococcus aureus pneumonia among hospitalized patients in the United States, 2009-2012.

David M Jacobs1, Amy Shaver2.   

Abstract

BACKGROUND: The burden of Staphylococcus aureus pneumonia is unknown despite being a major cause of mortality. We investigated national estimates of methicillin-resistant S aureus (MRSA) and methicillin-susceptible S aureus (MSSA) pneumonias and predictors of in-hospital mortality and hospital length of stay (LOS).
METHODS: This was a retrospective analysis of the National Inpatient Sample from 2009-2012. Adult patients with an ICD-9-CM primary diagnosis code for MRSA or MSSA pneumonia were included. Data weights were used to derive national estimates. Prevalence rates were reported per 100,000 hospital discharges, with trends presented descriptively.
RESULTS: There were 104,562 patients who had a primary diagnosis of S aureus pneumonia, with 81,275 from MRSA. MRSA pneumonia prevalence decreased steadily from 2009 (75.6 cases per 100,000 discharges) to 2012 (56.6 cases per 100,000 discharges), with MSSA pneumonia experiencing a slight decrease. Mortality rates decreased between 2009 and 2012 for MRSA pneumonia (7.9% to 6.4%) and MSSA pneumonia (6.9% to 4.7%; P = .008). LOS was higher for MRSA (6.9-7.8 days) compared with MSSA (6.1-6.4 days).
CONCLUSIONS: The prevalence of MRSA pneumonia has decreased among hospitalized adults in the United States in recent years accompanied by improvements in mortality and LOS. Although the prevalence of MRSA pneumonia is declining, national vigilance is still warranted.
Copyright © 2017 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MRSA; Pneumonia; Prevalence; Staphylococcus aureus

Mesh:

Year:  2016        PMID: 28041629     DOI: 10.1016/j.ajic.2016.11.014

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  6 in total

1.  The Daniel K. Inouye College of Pharmacy Scripts: The Effects of Vancomycin Use and De-escalation in Patients Hospitalized with Pneumonia.

Authors:  Aryn S You; Bryce T Fukunaga; Alexandra L Hanlon; Alicia J Lozano; Roy A Goo
Journal:  Hawaii J Med Public Health       Date:  2018-10

2.  Impact of a Pharmacist-Driven MRSA Nasal PCR Protocol on Pneumonia Therapy.

Authors:  Selena N Pham; Abby C Sturm; Joshua S Jacoby; Nnaemeka E Egwuatu; Lisa E Dumkow
Journal:  Hosp Pharm       Date:  2019-11-15

3.  12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus.

Authors:  Enrique Chacon-Cruz; Rosa Maria Rivas-Landeros; Maria Luisa Volker-Soberanes; Erika Zoe Lopatynsky-Reyes; Chandra Becka; Jorge Arturo Alvelais-Palacios
Journal:  Ther Adv Infect Dis       Date:  2019-04-03

4.  In-hospital mortality associated with community-acquired pneumonia due to methicillin-resistant Staphylococcus aureus: a matched-pair cohort study.

Authors:  Yukiyo Sakamoto; Yasuhiro Yamauchi; Taisuke Jo; Nobuaki Michihata; Wakae Hasegawa; Hideyuki Takeshima; Hiroki Matsui; Kiyohide Fushimi; Hideo Yasunaga; Takahide Nagase
Journal:  BMC Pulm Med       Date:  2021-11-03       Impact factor: 3.317

5.  Ceftriaxone resistance and adequacy of initial antibiotic therapy in community onset bacterial pneumonia.

Authors:  Richard F Van Besien; Nicholas Hampton; Scott T Micek; Marin H Kollef
Journal:  Medicine (Baltimore)       Date:  2022-05-20       Impact factor: 1.817

Review 6.  Exploring Virulence Factors and Alternative Therapies against Staphylococcus aureus Pneumonia.

Authors:  Jelle Vlaeminck; Dina Raafat; Kristin Surmann; Leen Timbermont; Nicole Normann; Bret Sellman; Willem J B van Wamel; Surbhi Malhotra-Kumar
Journal:  Toxins (Basel)       Date:  2020-11-18       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.